Distinguished in Embryonal Tumor with Multilayered Rosettes

Dr. Marta Penas-Prado

Neurology
1515 Holcombe Blvd, 
Houston, TX 
Distinguished in Embryonal Tumor with Multilayered Rosettes
1515 Holcombe Blvd, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marta Penas-Prado is a Neurologist in Houston, Texas. Dr. Penas-Prado is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Astrocytoma, Glioblastoma, Brain Tumor, Glioma, and Tissue Biopsy.

Her clinical research consists of co-authoring 96 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 9 articles and participated in 1 clinical trial in the study of Embryonal Tumor with Multilayered Rosettes.

Specialties
Neurology
Licenses
Psychiatry & Neurology in TX
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

1515 Holcombe Blvd, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-naïve Glioblastoma in the Adjuvant or Recurrent Setting
Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-naïve Glioblastoma in the Adjuvant or Recurrent Setting
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drugs: VAL-083, Dianhydrogalactitol
Study Phase: Phase 2
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Enrollment Status: Completed
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase I Lead-In to a 2x2x2 Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme
A Phase I Lead-In to a 2x2x2 Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme
Enrollment Status: Terminated
Publish Date: May 07, 2025
Intervention Type: Drug
Study Drugs: Mefloquine, Memantine Hydrochloride, Metformin Hydrochloride, Temozolomide
Study Phase: Phase 1
A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells for GBM Patients
A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells for GBM Patients
Enrollment Status: Completed
Publish Date: June 18, 2023
Intervention Type: Other, Drug, Biological, Procedure
Study Drugs: Autologous Cytomegalovirus-Specific Cytotoxic T Lymphocytes, Temozolomide
Study Phase: Phase 1/Phase 2
Phase II Study of Single-agent Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Phase II Study of Single-agent Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Enrollment Status: Completed
Publish Date: July 20, 2020
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients With High-Grade Gliomas
Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients With High-Grade Gliomas
Enrollment Status: Terminated
Publish Date: December 19, 2018
Intervention Type: Other, Drug
Study Phase: Not Applicable
View 5 Less Clinical Trials

96 Total Publications

Molecular, histologic, and clinical characterization of methylation class pleomorphic xanthoastrocytoma: An analysis of 469 tumors.
Molecular, histologic, and clinical characterization of methylation class pleomorphic xanthoastrocytoma: An analysis of 469 tumors.
Journal: Neuro-oncology advances
Published: July 30, 2025
Similar Doctors
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Shiao-pei Weathers
Neurology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Shiao-pei Weathers
Neurology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.6 miles away)
713-592-5433
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shiao-pei Weathers is a Neurologist in Houston, Texas. Dr. Weathers has been practicing medicine for over 16 years and is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Brain Tumor.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Nazanin Majd
Neurology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Nazanin Majd
Neurology

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
 (0.1 miles away)
713-792-2121
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nazanin Majd is a Neurologist in Houston, Texas. Dr. Majd is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Vinay K. Puduvalli
Neurology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Vinay K. Puduvalli
Neurology

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
 (0.1 miles away)
713-792-2121
Languages Spoken:
English
See accepted insurances

Vinay Puduvalli is a Neurologist in Houston, Texas. Dr. Puduvalli is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Gliomatosis Cerebri.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Penas-Prado's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile